Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Setbacks - Telix faced multiple regulatory challenges, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in stock value following the final news [2][7]. - The SEC is investigating the company's disclosures related to the development of its prostate cancer therapeutic candidates, suggesting misleading statements about their advancement [7]. Allegations of Misrepresentation - The lawsuit claims that Telix and its executives overstated the developmental progress of its therapeutic candidates and misrepresented the reliability of its third-party supply chain and manufacturing partners [2][3]. - The complaint alleges that the SEC questioned the development disclosures, while the FDA rejected a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][7]. Investor Impact - The cumulative effect of the regulatory disclosures reportedly caused significant financial damage to investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is actively advising investors who suffered substantial losses due to undisclosed flaws in the supply chain and therapeutic progress [5][6].

[Applause] I just wanted to ask because there's so many young people in the audience. Uh how many of you remember the 2010 floods. Not actually just watching it in the news but also experiencing it.So that's uh a lot of hands. That's great. That's great.So uh I'll tell you uh what I remember from the 2010 floods. Uh in July 2010 uh we were all watching the news and um we was we we could see floods were ravaging Sabad and Noer uh cities were being cut off and um it was a lot of people hundreds of thousands o ...